Clinical Trial

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-04-19; most recent amendment 2026-05-20.
Status change: Not Yet Recruiting → Recruiting 2024-12-03
Trial Details
NCT Number NCT06382155
Lead Sponsor BioMarin Pharmaceutical
Conditions Idiopathic Short Stature
Enrollment 100 participants
Start Date 2024-10-21
Primary Completion 2026-06 (estimated)
Study Completion 2036-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-22